65,437 trials
Vitiligo
Primary: Change in Pigmentation (Total and Individual Body Parts) Using the Vitiligo Area Scoring Index (VASI) — 0.00; 0.00; 0.00; 0.00 Change in VASI score from baseline
Multiple Myeloma
Primary: Evaluation of the Response Rate of Ixazomib With Metronomic Cyclophosphamide and Dexamethasone for First-line Treatment of Multiple Myeloma. — 12 Participants
Lung Neoplasm Malignant
Primary: Overall Step Count — 4707; 5605; 4606 Steps
Venous Thromboembolism · Haemorrhage
Primary: Incidence of Symptomatic Venous Thromboembolism Plus Asymptomatic Proximal Vein Thrombosis and All-cause Mortality — 1; 7 participants — p=0.03
Total Knee Arthroplasty
Primary: Cumulative Opioid Consumption — 4.8; 6.1 TME — p=0.0841
Alzheimer Disease
Primary: PET Amyloid Burden — -1.11 SUVR
Kidney Failure, Chronic
Primary: Number of Patients With Crossmatch Conversion (Positive to Negative) — 17; 2 Patients
Osteoporosis · Hypercholesterolemia
Primary: Relative Change in OPG/RANK/RANKL mRNA Expression in Isolated T Cells and Monocytes — 0.76 relative fold change — p=<0.05
Sleep-disordered Breathing
Primary: Diagnostic Sensitivity of Apnealink (AL) Compared With Polysomnography (PSG) — 91.5 percent of agreement between AL and PSG
Electronic Cigarettes
Primary: Change in Plasma Nicotine — 8.68; 8.28; 9.53; 12.00 ng/ml
Acute Respiratory Distress Syndrome · Cytokine Release Syndrome · Covid19
Primary: One-month Mortality Rate Between the Two Arms — 0; 3 participants
Septic Shock
Primary: Time to Resolution of Shock — 89; 84 Hours
Peripheral Arterial Disease
Primary: Number of Treated Lesions With Achievement of ≤ 50% Residual Stenosis Without Adjunctive Therapy — 3 lesion
Previously Untreated Peripheral T-cell Lymphoma
Primary: Complete Response Rate — 75 percentage of participants
Thrombocytopenia
Primary: Adverse Events (AEs) by Level of Severity — 8; 18; 6; 21 adverse events